Rani Therapeutics (RANI) AGM 2026 summary
Event summary combining transcript, slides, and related documents.
AGM 2026 summary
4 Jun, 2026Opening remarks and agenda
Meeting called to order with board members and management present, including CEO and CFO.
Inspector of Election appointed and rules of conduct outlined for an orderly virtual meeting.
Notice of meeting and quorum confirmed, with 123,872,874 shares eligible to vote.
Overview of voting outcomes
Election of seven directors approved to serve until the 2027 annual meeting.
Ratification of CBIZ CPAs, P.C. as independent auditor for fiscal year 2026 confirmed.
Voting results to be reported on Form 8-K within four business days.
Board and executive committee updates
Abraham Basan and Vasudev Bailey, PhD, appointed to the Board of Directors.
Alireza Javadi, PhD, promoted to Chief Technical Officer.
Advisory appointments of Dr. Sara Kenkare-Mitra and Jesper Høiland to strengthen leadership.
Latest events from Rani Therapeutics
- RT-114 shows >150% oral bioavailability; Q2 revenue up, cash at $53.4M, risks persist.RANI
Q2 2026 - Oral biologics platform shows >150% bioavailability in phase I-A, fueling major partnerships and pipeline growth.RANI
Canaccord Genuity's 46th Annual Growth Conference - Net loss narrowed to $8.0M on $1.7M revenue, with cash runway into Q4 2027 and Nasdaq delisting risk.RANI
Q1 2026 - Shareholders will vote on director elections and auditor ratification, with strong governance in place.RANI
Proxy filing - Vote on board elections and auditor ratification at the May 28, 2026 annual meeting.RANI
Proxy filing - Chugai deal, debt repayment, and clinical progress drive strong financial and pipeline momentum.RANI
Q4 2025 - Oral dual GLP-1/GLP-2 program targets obesity with weekly dosing, Phase 1 starts in 2025.RANI
Canaccord Genuity 44th Annual Growth Conference & Private Company Showcase 2024 - RT-114, an oral GLP-1/GLP-2 dual agonist, targets weekly dosing and global obesity market impact.RANI
Investor Update - Strong preclinical progress, reduced net loss, and RT-114 Phase 1 trial expected mid-2025.RANI
Q4 2024